RxDoctor Payments Data

Kenzie Scheidt, PA

Physician Assistant · Springfield, ORNPI 1992099824

Payments from drug & device makers

$3,048in general payments, 2019–2025

Across 139 payments — averaging $21.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$987
  • AstraZeneca$382
  • Novartis$320
  • Bristol Myers Squibb$315
  • Biotronik Inc.$173
  • Edwards Lifesciences$126
  • plus $745 from 16 others

What the payments were for

  • Travel & lodging$62521%
  • Food & beverage$2,34277%
  • Education$803%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,048 in reported general payments places this provider in the 90th percentile of 1,756 physician assistant providers in Oregon.

See all physician assistant providers in Oregon

Medicare billing

Part B allowed, 2024
$87,113
Medicare patients
559
Services billed
2,146

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban434$528,673
XareltoRivaroxaban79$85,963
JardianceEmpagliflozin41$61,692
Repatha SureclickEvolocumab79$51,292
EntrestoSacubitril/Valsartan31$40,061
Praluent PenAlirocumab22$19,339
FarxigaDapagliflozin Propanediol14$16,504
Flecainide Acetate156$7,116
Torsemide212$5,554
Metoprolol Succinate281$4,903
Atorvastatin Calcium298$3,467
Carvedilol308$3,325
Rosuvastatin Calcium182$3,317
Ezetimibe103$3,116
Diltiazem 24hr Er (Cd)Diltiazem Hcl57$2,307

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$48$528,673434 claims
Johnson & JohnsonXarelto$36$85,96379 claims
Boehringer IngelheimJardiance$54$61,69241 claims
NovartisEntresto$320$40,06131 claims
AstraZenecaFarxiga$382$16,50414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,756 physician assistant providers in Oregon.

Other physician assistant in Springfield

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →